A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

Phase 1

Completed

• Conditions: Neoplasms

• Registration Number: NCT00715403
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

The primary objective of this trial is to evaluate the long-term safety of BIBF 1120 in terms of incidence and intensity of Adverse Events and changes in safety laboratory parameters.

Secondary objectives are the collection of further safety data (vital signs), efficacy data and the determination of pharmacokinetic characteristics during long-term therapy with BIBF 1120.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2004-10
• Study First Submitted: 2008-07-11
• Study First Submitted QC: 2008-07-14
• Study First Posted: 2008-07-15
• Primary Completion: 2009-09
• Status Verified: 2014-11
• Results First Submitted: 2014-11-14
• Results First Submitted QC: 2014-11-24
• Last Update Submitted: 2014-11-24
• Results First Posted: 2014-12-02
• Last Update Posted: 2014-12-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 41

Inclusion Criteria

1. Male or female patients with advanced solid tumours who have completed a previous study with BIBF 1120. The patients should not have progression of their underlying tumour disease unless there is evidence for significant clinical benefit (e.g. symptom improvement) from treatment with BIBF 1120.
2. Age 18 years or older
3. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score <= 2
4. Patients must have given written informed consent (which must be consistent with ICH-GCP and local legislation)

Read More

Exclusion Criteria

1. Time elapsed from last administration of BIBF 1120 in the previous trial to start of treatment in the present trial exceeds four weeks
2. Presence of drug related toxicity > grade 2 CTC from previous therapy with BIBF 1120 or presence of drug related continuous toxicity of grade 2 for seven or more consecutive days which would preclude ongoing chronic therapy with BIBF 1120
3. Active ulcers (gastro-intestinal tract, skin)
4. Major injuries and surgery within the past three weeks with incomplete wound healing
5. Hypersensitivity to BIBF 1120 or the excipients of the trial drug
6. Known secondary malignancy requiring therapy
7. Active infectious disease
8. Significant cardiovascular diseases (i.e. uncontrolled severe hypertension, unstable angina pectoris, history of myocardial infarction, congestive heart failure > NYHA II)
9. Gastrointestinal disorders anticipated to interfere with the resorption of the study drug
10. Brain metastases requiring therapy
11. Absolute neutrophil count less than 1,500/mm3
12. Platelet count less than 100,000/mm3
13. Bilirubin greater than 1.5 mg/dl (> 26 µmol/L)
14. Aspartate amino transferase (AST) and/or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)
15. Serum creatinine greater than 2 mg/dl (> 176 µmol/L)
16. Concomitant non-oncological diseases which are considered relevant for the evaluation of the safety of the trial drug
17. Chemo-, radio-, or immunotherapy within the past four weeks prior to treatment with the trial drug
18. Patients who are sexually active and unwilling to use a medically acceptable method of contraception
19. Pregnancy or lactation
20. Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy (visit 2) or concomitantly with this trial (except for a previous study with BIBF 1120)
21. Patients unable to comply with the protocol
22. Active alcohol or drug abuse

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 2	From signing the informed consent until final follow-up, up to 991 days	All patients who had grade 2 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
Difference From Baseline for Bilirubin, Creatinine and Glucose	From signing the informed consent until end of treatment, up to 991 days	Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 1	From signing the informed consent until final follow-up, up to 991 days	All patients who had grade 1 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 3	From signing the informed consent until final follow-up, up to 991 days	All patients who had grade 3 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 4	From signing the informed consent until final follow-up, up to 991 days	All patients who had grade 4 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
Difference From Baseline for Haematology and Differentials Parameters	From signing the informed consent until end of treatment, up to 991 days	Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.
Difference From Baseline for Liver Enzymes	From signing the informed consent until end of treatment, up to 991 days	Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.
Difference From Baseline for Coagulation Parameters	From signing the informed consent until end of treatment, up to 991 days	Difference from baseline (normalized value) in coagulation parameters Prothrombin time, international normalised ratio (PT-INR) and partial thromboplastin time. Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.
Incidence and Intensity of Adverse Events With Highest CTCAE Grade 5	From signing the informed consent until final follow-up, up to 991 days	All patients who had grade 5 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE).
Difference From Baseline for Haemoglobin	From baseline until end of treatment, up to 991 days	Difference from baseline for Haemoglobin (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.
Difference From Baseline for Electrolytes	From signing the informed consent until end of treatment, up to 991 days	Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25.

Secondary Outcome Measures

Name	Time	Method
Clinically Relevant Abnormalities for Vital Signs	From baseline until final follow-up, up to 991 days	Clinically relevant abnormalities for Vital Signs (systolic blood pressure, diastolic blood pressure, and pulse rate). New abnormal findings or worsening of baseline conditions were reported as Adverse Events.
Confirmed Objective Response	Baseline until end of treatment, up to 991 days	Confirmed objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)
Unconfirmed Best Overall Response	Baseline until end of treatment, up to 991 days	Unconfirmed best overall response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0).; PD = Progressive disease.
Unconfirmed Best Objective Response	Baseline until end of treatment, up to 991 days	Unconfirmed best objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0)
Clinical Benefit	Baseline until end of treatment, up to 991 days	Clinical benefit was defined as the absence of disease progression (no PD or nonevaluable clinically progressive disease) determined by RECIST (version 1.0).
Pre-dose Concentration of Nintedanib in Plasma at Steady-state (Cpre,ss)	Just before drug administration every 28±7 days after day 29	Cpre,ss represents the pre-dose concentration of Nintedanib in Plasma at steady-state at day 29
Progression Free Survival	First drug administration (in previous trial) until end of treatment, up to 1230 days	Percentage of participants that experienced progression free survival (PFS), assessed by RECIST (Response Evaluation Criteria In Solid Tumours) (version 1.0), by day 1230. Progression was defined as progressive disease (PD) or non-evaluable clinically progressive disease.; PFS was defined for patients without PD at screening as the time from first treatment with the trial drug in the previous trial until onset of PD or death, whatever comes earlier.; Patients with PD could enter the trial if they showed signs of clinical benefit. For patients with PD at screening, the RECIST assessment at screening was used as a new baseline value and PFS was the time from first treatment with the trial drug in this trial until the onset of progressive disease in this trial or death, whatever comes first.

Trial Locations

Locations (11)

1199.16.49004 Boehringer Ingelheim Investigational Site; 🇩🇪 Grosshansdorf, Germany

1199.16.3306A Boehringer Ingelheim Investigational Site; 🇫🇷 Bordeaux cedex, France

1199.16.3311B Boehringer Ingelheim Investigational Site; 🇫🇷 Clichy Cedex, France

1199.16.3311A Boehringer Ingelheim Investigational Site; 🇫🇷 Clichy Cedex, France

1199.16.3313A Boehringer Ingelheim Investigational Site; 🇫🇷 Paris Cedex 10, France

1199.16.3313E Boehringer Ingelheim Investigational Site; 🇫🇷 Paris Cedex 10, France

1199.16.3302A Boehringer Ingelheim Investigational Site; 🇫🇷 Paris cedex 15, France

1199.16.3312A Boehringer Ingelheim Investigational Site; 🇫🇷 Paris, France

1199.16.49001 Boehringer Ingelheim Investigational Site; 🇩🇪 Freiburg/Breisgau, Germany

1199.16.49008 Boehringer Ingelheim Investigational Site; 🇩🇪 Tübingen, Germany

1199.16.49005 Boehringer Ingelheim Investigational Site; 🇩🇪 Wiesbaden, Germany